Inflammatory and Long-term Risk Markers

Clinics in Laboratory Medicine

Volumn 26, Issue 3, 2006, Pages 553-570

  Levinson, Stanley S ^a  

^a Laboratory Service   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; FIBRINOGEN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; HUMAN; INFLAMMATION; LIPID OXIDATION; METABOLIC SYNDROME X; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THROMBOSIS;

ACUTE-PHASE PROTEINS; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; HUMANS; INFLAMMATION; LIPOPROTEINS, LDL; RISK FACTORS;

EID: 33747835595     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2006.06.001     Document Type: Review

References (100)

1. Mahley R.W., and Zhong-Sheng J. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 40 (1999) 1-16
2. Sniderman A.D. Apolipoprotein B versus non-high density lipoprotein cholesterol. Circulation 112 (2005) 3366-3367
3. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
4. Zaman A.G., Helft G., Worthley S.G., et al. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis 149 (2000) 251-266
5. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). ATP III Final Report. Circulation 106 (2002) 3145-3234
6. Mangge H., Hubmann H., Pilz S., et al. Beyond cholesterol-inflammatory cytokines, the key mediators in atherosclerosis. Clin Chem Lab Med 42 (2004) 467-474
7. Rauch U., Osende J.I., Chesebro J.H., et al. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis 153 (2000) 181-189
8. Stenestrand U., and Wallentin L. Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 285 (2001) 430-436
9. Chisolm G.M., and Steinberg D. The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28 (2000) 1815-1826
10. Kritharides L., and Stocker R. The use of antioxidant supplements in coronary heart disease. Atherosclerosis 164 (2002) 211-219
11. Brown B.G., Cheung M.C., Lee A.C., et al. Antioxidant vitamins and lipid therapy: end of a long romance?. Arterioscler Thromb Vasc Biol 22 (2002) 1535-1546
12. Jialal I., and Devaraj S. Antioxidants and arteriosclerosis. Don't throw out the baby with the bath water. Circulation 107 (2003) 926-928
13. Tracy R.P. Inflammation in cardiovascular disease. Cart, horse, or both. [editorial]. Circulation 97 (1998) 2000-2002
14. Danesh J., Collins R., Appleby P., et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279 (1998) 1477-1482
15. Gabay C., and Kushner I. Acute phase proteins and other systemic responses to inflammation. N Engl J Med 40 (1999) 448-454
16. Jousilahti P., Salomaa V., Rasi V., et al. The association of C-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease-baseline findings of the PAIS project. Atherosclerosis 156 (2001) 451-456
17. Ridker P.M., Stampfer M.J., and Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285 (2001) 2481-2485
18. Luc G., Bard J.M., Juhan-Vague I., et al. PRIME Study Group. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 23 (2003) 1255-1261
19. Ridker P.M., Hennekens C.H., Buring J.E., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in woman. N Engl J Med 342 (2000) 836-842
20. Schillinger M., Exner M., Mlekusch W., et al. Inflammation and Carotid Artery-Risk for Atherosclerosis Study (ICARAS). Circulation 111 (2005) 2203-2209
21. Heinrich P.C., Castell J.V., and Andus T. Interleukin-6 and the acute phase response. Biochem J 265 (1990) 621-636
22. Nicholls S.J., and Hazen S.L. Meloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 25 (2005) 1102-1111
23. Zhang R., Brennan M.L., Fu X., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286 (2001) 2136-2142
24. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 91 3A Suppl (2003) 3A-6A
25. Schönbeck U., Varo N., Libby P., et al. Soluble CD40L and cardiovascular risk in women. Circulation 104 (2001) 2266-2268
26. Ledue T.B., and Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem 49 (2003) 1258-1271
27. Loyer P., Ilyin G., Abdel Razzak Z., et al. Interleukin 4 inhibits the production of some acute-phase proteins by human hepatocytes in primary culture. FEBS Lett 336 (1993) 215-220
28. Barnes P.J., and Karin M. Nuclear factor-κB-a pivotal transcription factor in chronic inflammatory disease. N Engl J Med 336 (1997) 1066-1071
29. Kannel W.B., Wolf P., Castelli P., et al. Fibrinogen and risk of cardiovascular disease. JAMA 258 (1987) 1183-1186
30. Yarnell J.W.B., Baker I.A., Sweetnam P.M., et al. Fibrinogen viscosity and white blood cell count are major risk actors for ischemic heart disease. Circulation 83 (1991) 836-844
31. Ma J., Hennekens C.H., Ridker P.M., et al. A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study. J Am Coll Cardiol 33 (1999) 1347-1352
32. Danesh J., Lewington S., Thompson S.G., et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294 (2005) 1799-1809 [erratum in JAMA 2005;294:2848]
33. Lee A.J., Mowbray P.I., Lowe G.D., et al. Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study. Circulation 97 (1998) 1467-1473
34. Ernst E. Plasma fibrinogen-an independent cardiovascular risk factor. J Intern Med 227 (1990) 365-372
35. Stec J.J., Silbershatz H., Tofler G.H., et al. Association of fibrinogen with cardiovascular risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation 102 (2000) 1634-1638
36. Heinrich J., Balleisen L., Schulte H., et al. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 14 (1994) 54-59
37. Olinescu R., Nita S., Popovici D., et al. The antioxidative action of fibrinogen and the implications of the effect on platelet aggregation. Rev Roum Med Intern 32 (1994) 185-193
38. Shacter E., Williams J.A., Lim M., et al. Differential susceptibility of plasma proteins to oxidative modification: examination by Western blot immunoassay. Free Rad Biol Med 17 (1994) 429-437
39. Olinescu R.M., and Kummerow F.A. Fibrinogen is an efficient antioxidant. J Nutrit Biochem 12 (2001) 162-169
40. Kaplan I.V., Attaelmannan M., and Levinson S.S. Fibrinogen is an antioxidant that protects β-lipoproteins at physiological concentrations in an in vitro cell free system. Atherosclerosis 158 (2001) 455-463
41. Pepys M.B., and Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 111 (2003) 1805-1812
42. Black S., Kushner I., and Samols D. C-reactive protein. J Biol Chem 47 (2004) 48487-48490
43. Abudu N., Miller J.J., and Levinson S.S. Vitamins in human arteriosclerosis with emphasis on vitamin C and vitamin E. Clin Chim Acta 339 (2004) 11-25
44. Tall A.R. C-reactive protein reassessed. N Engl J Med 350 (2004) 1450-1452
45. Taylor K.E., Giddings J.C., and van den Berg C.W. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 25 (2005) 1225-1230
46. Pepys M.B. CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol 25 (2005) 1091-1094
47. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
48. Ridker P.M., Glynn R.J., and Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97 (1998) 2007-2011
49. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive potein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350 (2004) 1387-1397
50. Rifai N., and Ridker P.M. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem 47 (2001) 28-30
51. Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107 (2003) 363-369
52. Ridker P.M., Wilson P.W., and Grundy S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 109 (2004) 2818-2825
53. Ridker P.M., Hennekens C.H., Rifai N., et al. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100 (1999) 713-716
54. Visser M., Bouter L.M., McQuillan G.M., et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 282 (1999) 2131-2135
55. Hak A.E., Stehouwer C.D., Bots M., et al. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 19 (1999) 1986-1991
56. Koenig W., Sund M., Fröhlich M., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg cohort study, 1984 to 1992. Circulation 99 (1999) 237-242
57. Pradhan A.D., Manson J.E., Rifai N., et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286 (2001) 327-334
58. Chung M.K., Martin D.O., Sprecher D., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104 (2001) 2886-2891
59. Reilly M.P., Wolfe M.L., Rhodes T., et al. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 110 (2004) 803-809
60. Shamsuzzaman A.S., Winnicki M., Lanfranchi P., et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 105 (2002) 2462-2464
61. Sesso H.D., Buring J.E., Rifai N., et al. C-reactive protein and the risk of developing hypertension. JAMA 290 (2003) 2945-2951
62. Kereiakes D.J., and Willerson J.T. Metabolic syndrome epidemic. Circulation 108 (2003) 1552-1553
63. Reilly M.P., and Rader D.J. The metabolic syndrome. More than the sum of its parts?. Circulation 108 (2003) 1546-1551
64. Wilson P.W.F., and Grundy S.M. The metabolic syndrome. Circulation 108 (2003) 1537-1540
65. Ridker P.M., Buring J.E., Cook N.R., et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14719 initially healthy American women. Circulation 107 (2003) 391-397
66. Levinson S.S., Miller J.J., and Elin R.J. Poor predictive value of hs-C reactive protein denotes need for reassessment. Clin Chem 50 (2004) 1733-1735
67. Rutter M.K., Meigs J.B., Sullivan L.M., et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110 (2004) 380-385
68. Ridker P.M., and Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 109 (2004) 1955-1959
69. Ford E.S., Giles W.H., Mokdad A.H., et al. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem 50 (2004) 574-581
70. Woloshin S., and Schwartz L.M. Distributions of C-reactive protein values in the United States. N Engl J Med 352 (2005) 1611-1613
71. Levinson S.S., and Elin R.J. What is the acute phase reactant C-reactive protein telling us about atherosclerosis?. Arch Intern Med 162 (2002) 389-392
72. Hackman D.G., and Anand S.S. Emerging risk factors for atherosclerotic disease. A critical review of the evidnce. JAMA 290 (2003) 932-940
73. St-Pierre A.C., Cantin B., Bergeron J., et al. Inflammatory markers and long-term risk of ischemic heart disease in men. A 13-year follow-up of the Quebec Cardiovascular Study. Atherosclerosis 182 (2005) 315-321
74. Pradhan A.D., Manson J.E., Rossouw J.E., et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA 288 (2002) 980-987
75. Ridker P.M., Rifai N., Stampfer M.J., et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
76. Heinecke J.W. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 1441 (1998) 1-15
77. Abudu N., Miller J.J., and Levinson S.S. Lipoprotein oxidation products and arteriosclerosis: theory and methods with applicability to the clinical chemistry laboratory. Adv Clin Chem 38 (2004) 1-35
78. Heinecke J.W. Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall. FASEB J 13 (1999) 1113-1120
79. Ridker P.M., Buring J.E., Shih J., et al. Prospective study of C-reactive protein and risk of future cardiovascular events among apparently healthy women. Circulation 98 (1998) 731-733
80. Baldus S., Heeschen C., Meinertz T., et al. CAPTURE investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 108 (2003) 1440-1445
81. André P., Nannizzi-Alaimo L., Prasad S.K., et al. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106 (2002) 896-899
82. Mach F., Schönbeck U., Sukhova G.K., et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394 (1998) 200-203
83. Garlichs C.D., John S., Schmeisser A., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104 (2001) 2395-2400
84. Semb A.G., van Wissen S., Ueland T., et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy. J Am Coll Cardiol 41 (2003) 275-279
85. Aukrust P., Muller F., Ueland T., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 (1999) 614-620
86. Heeschen C., Dimmeler S., and Hamm C.W. CAPTURE study investigators. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
87. de Lemos J.A., Zirlik A., Schonbeck U., et al. Associations between soluble CD40 ligand, atherosclerosis risk factors, and subclinical atherosclerosis: results from the Dallas Heart Study. Arterioscler Thromb Vasc Biol 25 (2005) 2192-2196
88. Hanley J.A., and McNeil B.J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143 (1982) 29-36
89. Swets J.A. Measuring the accuracy of diagnostic systems. Science 240 (1988) 1286-1293
90. Vecchio T.J. Predictive value of a single diagnostic test in unselected populations. N Engl J Med 274 (1966) 1171-1173
91. Sackett D.L., and Haynes R.B. Evidence base of clinical diagnosis. The architecture of diagnostic research. BMJ 324 (2002) 539-541
92. Mosca L. C-reactive protein-to screen or not to screen?. N Engl J Med 347 (2002) 1615-1617
93. Pepys M.B. Hard-hearted CRP. J Clin Invest 113 (2004) 1244-1245
94. Wang T.J., Nam B.H., Wilson P.W., et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 22 (2002) 1662-1667
95. Loscalzo J. Clinical trials in cardiovascular medicine in an era of marginal benefit, bias, and hyperbole. Circulation 115 (2005) 3026-3029
96. Steinberg D. An interpretive history of the cholesterol controversity, part III: mechanically defining the role of hyperlipidemia. J Lipid Res 46 (2005) 2037-2051
97. Pearson T.A., Mensah G.A., Alexander R.W., et al. Centers for Disease Control and Prevention. American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 (2003) 499-511
98. Garcia-Moll X., and Ordonez-Lianos J. Role of hs-CRP measurements in the current cardiovascular risk assessment. Clin Chim Acta 355 (2005) 215-218
99. Koenig W., Lowel H., Baumert J., et al. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109 (2004) 1349-1353
100. Cushman M., Arnold A.M., Psaty B.M., et al. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation 112 (2005) 25-31